Complement-dependent T-cell Lymphopenia caused by thymocyte deletion of the membrane complement regulator Crry

Blood

Volumn 113, Issue 12, 2009, Pages 2684-2694

  Miwa, Takashi ^a   Zhou, Lin ^a   Kimura, Yuko ^a   Kim, David ^a   Bhandoola, Avinash ^a   Song, Wen Chao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; LIGANDIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE TARGETING; HYPERSENSITIVITY; LYMPHOCYTOPENIA; MACROPHAGE; MALE; MOUSE; MURINAE; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOPENIA; T LYMPHOCYTE; THYMOCYTE; THYMUS;

EID: 63849307505     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-157966     Document Type: Article

References (37)

1. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058-1066.
2. Song WC, Sarrias MR, Lambris JD. Complement and innate immunity. Immunopharmacology. 2000;49:187-198.
3. Mollnes TE, Song WC, Lambris JD. Complement in inflammatory tissue damage and disease. Trends Immunol. 2002;23:61-64.
4. Hourcade D, Holers VM, Atkinson JP. The regulators of complement activation (RCA) gene cluster. Adv Immunol. 1989;45:381-416.
5. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol. 2006;118:127-136.
6. Miwa T, Song WC. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol. 2001;1:445-459.
7. Giannakis E, Male DA, Ormsby RJ, et al. Multiple ligand binding sites on domain seven of human complement factor H. Int Immunopharmacol. 2001;1:433-443.
8. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344:1140-1144.
9. Molina H. The murine complement regulator Crry: new insights into the immunobiology of complement regulation. Cell Mol Life Sci. 2002;59:220-229.
10. Li B, Sallee C, Dehoff M, Foley S, Molina H, Holers VM. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol. 1993;151:4295-4305.
11. Kim YU, Kinoshita T, Molina H, et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med. 1995;181:151-159.
12. Miwa T, Nonaka M, Okada N, Wakana S, Shiroishi T, Okada H. Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1. Immunogenetics. 1998;48:363-371.
13. Tsujimura A, Shida K, Kitamura M, et al. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem J. 1998;330:163-168.
14. Holers VM, Kinoshita T, Molina H. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol Today. 1992;13:231-236.
15. Fremeaux-Bacchi V, Moulton EA, Kavanagh D, et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2006;17:2017-2025.
16. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science. 2000;287:498-501.
17. Kimura Y, Miwa T, Zhou L, Song WC. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood. 2008;111:732-740.
18. Miwa T, Zhou L, Hilliard B, Molina H, Song WC. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Blood. 2002;99:3707-3716.
19. Rodriguez CI, Buchholz F, Galloway J, et al. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet. 2000;25:139-140.
20. Zhang X, Kimura Y, Fang C, et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood. 2007;110:228-236.
21. Molina H, MiwaT, Zhou L, et al. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor. Blood. 2002;100:4544-4549.
22. Helmy KY, Katschke KJ Jr, Gorgani NN, et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell. 2006;124:915-927.
23. Seiler P, Aichele P, Odermatt B, Hengartner H, Zinkernagel RM, Schwendener RA. Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur J Immunol. 1997;27:2626-2633.
24. Kim DD, Miwa T, Kimura Y, Schwendener RA, van Lookeren Campagne M, Song WC. Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg. Blood. 2008;112:1109-1119.
25. Paul MS, Aegerter M, Cepek K, Miller MD, Weis JH. The murine complement receptor gene family, III: the genomic and transcriptional complexity of the Crry and Crry-ps genes. J Immunol. 1990;144:1988-1996.
26. Hepburn NJ, Chamberlain-Banoub JL, Williams AS, Morgan BP, Harris CL. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo. Mol Immunol. 2008;45:395-405.
27. O'Gorman S, Fox DT, Wahl GM. Recombinase-mediated gene activation and site-specific integration in mammalian cells. Science. 1991;251:1351-1355.
28. Hennet T, Hagen FK, Tabak LA, Marth JD. T-cell-specific deletion of a polypeptide N-acetylgalactosaminyl-transferase gene by site-directed recombination. Proc Natl Acad Sci USA. 1995;92:12070-12074.
29. Lee PP, Fitzpatrick DR, Beard C, et al. Acritical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity. 2001;15:763-774.
30. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature. 1994;372:100-103.
31. Platt N, Suzuki H, Kurihara Y, Kodama T, Gordon S. Role for the class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes in vitro. Proc Natl Acad Sci U S A. 1996;93:12456-12460.
32. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci USA. 1999;96:628-633.
33. Miwa T, Sun X, Ohta R, et al. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity. Immunology. 2001;104:207-214.
34. Le Gros GS, Prestidge RL, Watson JD. In-vivo modulation of thymus-derived lymphocytes with monoclonal antibodies in mice, I: effect of anti-Thy-1 antibody on the tissue distribution of lymphocytes. Immunology. 1983;50:537-546.
35. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823-3837.
36. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171:1581-1587.
37. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. [see comment]. Haematologica. 2006;91:176-183.